Socioeconomic benefit to individuals of achieving 2020 targets for four neglected tropical diseases controlled/eliminated by innovative and intensified disease management: Human African trypanosomiasis, leprosy, visceral leishmaniasis, Chagas disease

Edeltraud J. Lenk, William K. Redekop, Marianne Luyendijk, Christopher Fitzpatrick, Louis Niessen, Wilma A. Stolk, Fabrizio Tediosi, Adriana J. Rijnsburger, Roel Bakker, Jan A.C. Hontelez, Jan H. Richardus, Julie Jacobson, Epke A. Le Rutte, Sake J. de Vlas, Johan L. Severens

Research output: Contribution to journalArticle

Abstract

Background: The control or elimination of neglected tropical diseases (NTDs) has targets defined by the WHO for 2020, reinforced by the 2012 London Declaration. We estimated the economic impact to individuals of meeting these targets for human African trypanosomiasis, leprosy, visceral leishmaniasis and Chagas disease, NTDs controlled or eliminated by innovative and intensified disease management (IDM). Methods: A systematic literature review identified information on productivity loss and out-of-pocket payments (OPPs) related to these NTDs, which were combined with projections of the number of people suffering from each NTD, country and year for 2011–2020 and 2021–2030. The ideal scenario in which the WHO’s 2020 targets are met was compared with a counterfactual scenario that assumed the situation of 1990 stayed unaltered. Economic benefit equaled the difference between the two scenarios. Values are reported in 2005 US$, purchasing power parity-adjusted, discounted at 3% per annum from 2010. Probabilistic sensitivity analyses were used to quantify the degree of uncertainty around the base-case impact estimate. Results: The total global productivity gained for the four IDM-NTDs was I$ 23.1 (I$ 15.9 –I$ 34.0) billion in 2011–2020 and I$ 35.9 (I$ 25.0 –I$ 51.9) billion in 2021–2030 (2.5thand 97.5thpercentiles in brackets), corresponding to US$ 10.7 billion (US$ 7.4 –US$ 15.7) and US$ 16.6 billion (US$ 11.6 –US$ 24.0). Reduction in OPPs was I$ 14 billion (US$ 6.7 billion) and I$ 18 billion (US$ 10.4 billion) for the same periods. Conclusions: We faced important limitations to our work, such as finding no OPPs for leprosy. We had to combine limited data from various sources, heterogeneous background, and of variable quality. Nevertheless, based on conservative assumptions and subsequent uncertainty analyses, we estimate that the benefits of achieving the targets are considerable. Under plausible scenarios, the economic benefits far exceed the necessary investments by endemic country governments and their development partners. Given the higher frequency of NTDs among the poorest households, these investments represent good value for money in the effort to improve well-being, distribute the world’s prosperity more equitably and reduce inequity.

Original languageEnglish (US)
Article numbere0006250
JournalPLoS Neglected Tropical Diseases
Volume12
Issue number3
DOIs
StatePublished - Mar 13 2018
Externally publishedYes

Fingerprint

Neglected Diseases
African Trypanosomiasis
Visceral Leishmaniasis
Chagas Disease
Leprosy
Disease Management
Health Expenditures
Economics
Uncertainty
Information Storage and Retrieval
Parity

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health
  • Infectious Diseases

Cite this

Socioeconomic benefit to individuals of achieving 2020 targets for four neglected tropical diseases controlled/eliminated by innovative and intensified disease management : Human African trypanosomiasis, leprosy, visceral leishmaniasis, Chagas disease. / Lenk, Edeltraud J.; Redekop, William K.; Luyendijk, Marianne; Fitzpatrick, Christopher; Niessen, Louis; Stolk, Wilma A.; Tediosi, Fabrizio; Rijnsburger, Adriana J.; Bakker, Roel; Hontelez, Jan A.C.; Richardus, Jan H.; Jacobson, Julie; Le Rutte, Epke A.; de Vlas, Sake J.; Severens, Johan L.

In: PLoS Neglected Tropical Diseases, Vol. 12, No. 3, e0006250, 13.03.2018.

Research output: Contribution to journalArticle

Lenk, EJ, Redekop, WK, Luyendijk, M, Fitzpatrick, C, Niessen, L, Stolk, WA, Tediosi, F, Rijnsburger, AJ, Bakker, R, Hontelez, JAC, Richardus, JH, Jacobson, J, Le Rutte, EA, de Vlas, SJ & Severens, JL 2018, 'Socioeconomic benefit to individuals of achieving 2020 targets for four neglected tropical diseases controlled/eliminated by innovative and intensified disease management: Human African trypanosomiasis, leprosy, visceral leishmaniasis, Chagas disease', PLoS Neglected Tropical Diseases, vol. 12, no. 3, e0006250. https://doi.org/10.1371/journal.pntd.0006250
Lenk, Edeltraud J. ; Redekop, William K. ; Luyendijk, Marianne ; Fitzpatrick, Christopher ; Niessen, Louis ; Stolk, Wilma A. ; Tediosi, Fabrizio ; Rijnsburger, Adriana J. ; Bakker, Roel ; Hontelez, Jan A.C. ; Richardus, Jan H. ; Jacobson, Julie ; Le Rutte, Epke A. ; de Vlas, Sake J. ; Severens, Johan L. / Socioeconomic benefit to individuals of achieving 2020 targets for four neglected tropical diseases controlled/eliminated by innovative and intensified disease management : Human African trypanosomiasis, leprosy, visceral leishmaniasis, Chagas disease. In: PLoS Neglected Tropical Diseases. 2018 ; Vol. 12, No. 3.
@article{4cb7b08226ac42da9e92be241424d0c3,
title = "Socioeconomic benefit to individuals of achieving 2020 targets for four neglected tropical diseases controlled/eliminated by innovative and intensified disease management: Human African trypanosomiasis, leprosy, visceral leishmaniasis, Chagas disease",
abstract = "Background: The control or elimination of neglected tropical diseases (NTDs) has targets defined by the WHO for 2020, reinforced by the 2012 London Declaration. We estimated the economic impact to individuals of meeting these targets for human African trypanosomiasis, leprosy, visceral leishmaniasis and Chagas disease, NTDs controlled or eliminated by innovative and intensified disease management (IDM). Methods: A systematic literature review identified information on productivity loss and out-of-pocket payments (OPPs) related to these NTDs, which were combined with projections of the number of people suffering from each NTD, country and year for 2011–2020 and 2021–2030. The ideal scenario in which the WHO’s 2020 targets are met was compared with a counterfactual scenario that assumed the situation of 1990 stayed unaltered. Economic benefit equaled the difference between the two scenarios. Values are reported in 2005 US$, purchasing power parity-adjusted, discounted at 3{\%} per annum from 2010. Probabilistic sensitivity analyses were used to quantify the degree of uncertainty around the base-case impact estimate. Results: The total global productivity gained for the four IDM-NTDs was I$ 23.1 (I$ 15.9 –I$ 34.0) billion in 2011–2020 and I$ 35.9 (I$ 25.0 –I$ 51.9) billion in 2021–2030 (2.5thand 97.5thpercentiles in brackets), corresponding to US$ 10.7 billion (US$ 7.4 –US$ 15.7) and US$ 16.6 billion (US$ 11.6 –US$ 24.0). Reduction in OPPs was I$ 14 billion (US$ 6.7 billion) and I$ 18 billion (US$ 10.4 billion) for the same periods. Conclusions: We faced important limitations to our work, such as finding no OPPs for leprosy. We had to combine limited data from various sources, heterogeneous background, and of variable quality. Nevertheless, based on conservative assumptions and subsequent uncertainty analyses, we estimate that the benefits of achieving the targets are considerable. Under plausible scenarios, the economic benefits far exceed the necessary investments by endemic country governments and their development partners. Given the higher frequency of NTDs among the poorest households, these investments represent good value for money in the effort to improve well-being, distribute the world’s prosperity more equitably and reduce inequity.",
author = "Lenk, {Edeltraud J.} and Redekop, {William K.} and Marianne Luyendijk and Christopher Fitzpatrick and Louis Niessen and Stolk, {Wilma A.} and Fabrizio Tediosi and Rijnsburger, {Adriana J.} and Roel Bakker and Hontelez, {Jan A.C.} and Richardus, {Jan H.} and Julie Jacobson and {Le Rutte}, {Epke A.} and {de Vlas}, {Sake J.} and Severens, {Johan L.}",
year = "2018",
month = "3",
day = "13",
doi = "10.1371/journal.pntd.0006250",
language = "English (US)",
volume = "12",
journal = "PLoS Neglected Tropical Diseases",
issn = "1935-2727",
publisher = "Public Library of Science",
number = "3",

}

TY - JOUR

T1 - Socioeconomic benefit to individuals of achieving 2020 targets for four neglected tropical diseases controlled/eliminated by innovative and intensified disease management

T2 - Human African trypanosomiasis, leprosy, visceral leishmaniasis, Chagas disease

AU - Lenk, Edeltraud J.

AU - Redekop, William K.

AU - Luyendijk, Marianne

AU - Fitzpatrick, Christopher

AU - Niessen, Louis

AU - Stolk, Wilma A.

AU - Tediosi, Fabrizio

AU - Rijnsburger, Adriana J.

AU - Bakker, Roel

AU - Hontelez, Jan A.C.

AU - Richardus, Jan H.

AU - Jacobson, Julie

AU - Le Rutte, Epke A.

AU - de Vlas, Sake J.

AU - Severens, Johan L.

PY - 2018/3/13

Y1 - 2018/3/13

N2 - Background: The control or elimination of neglected tropical diseases (NTDs) has targets defined by the WHO for 2020, reinforced by the 2012 London Declaration. We estimated the economic impact to individuals of meeting these targets for human African trypanosomiasis, leprosy, visceral leishmaniasis and Chagas disease, NTDs controlled or eliminated by innovative and intensified disease management (IDM). Methods: A systematic literature review identified information on productivity loss and out-of-pocket payments (OPPs) related to these NTDs, which were combined with projections of the number of people suffering from each NTD, country and year for 2011–2020 and 2021–2030. The ideal scenario in which the WHO’s 2020 targets are met was compared with a counterfactual scenario that assumed the situation of 1990 stayed unaltered. Economic benefit equaled the difference between the two scenarios. Values are reported in 2005 US$, purchasing power parity-adjusted, discounted at 3% per annum from 2010. Probabilistic sensitivity analyses were used to quantify the degree of uncertainty around the base-case impact estimate. Results: The total global productivity gained for the four IDM-NTDs was I$ 23.1 (I$ 15.9 –I$ 34.0) billion in 2011–2020 and I$ 35.9 (I$ 25.0 –I$ 51.9) billion in 2021–2030 (2.5thand 97.5thpercentiles in brackets), corresponding to US$ 10.7 billion (US$ 7.4 –US$ 15.7) and US$ 16.6 billion (US$ 11.6 –US$ 24.0). Reduction in OPPs was I$ 14 billion (US$ 6.7 billion) and I$ 18 billion (US$ 10.4 billion) for the same periods. Conclusions: We faced important limitations to our work, such as finding no OPPs for leprosy. We had to combine limited data from various sources, heterogeneous background, and of variable quality. Nevertheless, based on conservative assumptions and subsequent uncertainty analyses, we estimate that the benefits of achieving the targets are considerable. Under plausible scenarios, the economic benefits far exceed the necessary investments by endemic country governments and their development partners. Given the higher frequency of NTDs among the poorest households, these investments represent good value for money in the effort to improve well-being, distribute the world’s prosperity more equitably and reduce inequity.

AB - Background: The control or elimination of neglected tropical diseases (NTDs) has targets defined by the WHO for 2020, reinforced by the 2012 London Declaration. We estimated the economic impact to individuals of meeting these targets for human African trypanosomiasis, leprosy, visceral leishmaniasis and Chagas disease, NTDs controlled or eliminated by innovative and intensified disease management (IDM). Methods: A systematic literature review identified information on productivity loss and out-of-pocket payments (OPPs) related to these NTDs, which were combined with projections of the number of people suffering from each NTD, country and year for 2011–2020 and 2021–2030. The ideal scenario in which the WHO’s 2020 targets are met was compared with a counterfactual scenario that assumed the situation of 1990 stayed unaltered. Economic benefit equaled the difference between the two scenarios. Values are reported in 2005 US$, purchasing power parity-adjusted, discounted at 3% per annum from 2010. Probabilistic sensitivity analyses were used to quantify the degree of uncertainty around the base-case impact estimate. Results: The total global productivity gained for the four IDM-NTDs was I$ 23.1 (I$ 15.9 –I$ 34.0) billion in 2011–2020 and I$ 35.9 (I$ 25.0 –I$ 51.9) billion in 2021–2030 (2.5thand 97.5thpercentiles in brackets), corresponding to US$ 10.7 billion (US$ 7.4 –US$ 15.7) and US$ 16.6 billion (US$ 11.6 –US$ 24.0). Reduction in OPPs was I$ 14 billion (US$ 6.7 billion) and I$ 18 billion (US$ 10.4 billion) for the same periods. Conclusions: We faced important limitations to our work, such as finding no OPPs for leprosy. We had to combine limited data from various sources, heterogeneous background, and of variable quality. Nevertheless, based on conservative assumptions and subsequent uncertainty analyses, we estimate that the benefits of achieving the targets are considerable. Under plausible scenarios, the economic benefits far exceed the necessary investments by endemic country governments and their development partners. Given the higher frequency of NTDs among the poorest households, these investments represent good value for money in the effort to improve well-being, distribute the world’s prosperity more equitably and reduce inequity.

UR - http://www.scopus.com/inward/record.url?scp=85045113523&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85045113523&partnerID=8YFLogxK

U2 - 10.1371/journal.pntd.0006250

DO - 10.1371/journal.pntd.0006250

M3 - Article

C2 - 29534061

AN - SCOPUS:85045113523

VL - 12

JO - PLoS Neglected Tropical Diseases

JF - PLoS Neglected Tropical Diseases

SN - 1935-2727

IS - 3

M1 - e0006250

ER -